StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.46−0.09 (-15.97%)

Close on Nov 17, 2026Market cap $830.71KP/E –Yield –

Aptevo Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Aptevo Therapeutics's gross margin for the twelve months ending Dec 31, 2019 was 38.5%. For fiscal 2019 it was 38.5%, against 51.4% the year before. The highest annual figure on record is 65.8% in fiscal 2017.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2019Dec 31, 201938.5%−12.8
FY2018Dec 31, 201851.4%−14.4
FY2017Dec 31, 201765.8%+90.7
FY2016Dec 31, 2016-24.9%−74.5
FY2015Dec 31, 201549.6%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2019Dec 31, 201932.1%+2.4
Q3 FY2019Sep 30, 201956.1%−2.1
Q2 FY2019Jun 30, 201918.7%−44.2
Q1 FY2019Mar 31, 201945.2%−11.0
Q4 FY2018Dec 31, 201829.7%−3.0
Q3 FY2018Sep 30, 201858.2%−11.5
Q2 FY2018Jun 30, 201862.9%+130.1
Q1 FY2018Mar 31, 201856.3%−21.0
Q4 FY2017Dec 31, 201732.7%−9.4
Q3 FY2017Sep 30, 201769.7%+115.6
Q2 FY2017Jun 30, 2017-67.2%–
Q1 FY2017Mar 31, 201777.2%–
Q4 FY2016Dec 31, 201642.1%–
Q3 FY2016Sep 30, 2016-46.0%–

More Aptevo Therapeutics figures

See a number that looks wrong?